Phase II, Modified Single-Blind, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Cerebral Efficacy of CPC-201 in Patients With Alzheimer's Disease Type Dementia: PET Study

Trial Profile

Phase II, Modified Single-Blind, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Cerebral Efficacy of CPC-201 in Patients With Alzheimer's Disease Type Dementia: PET Study

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Donepezil/solifenacin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Chase Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 12 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top